Physician profile
Gladys Kimeli
NPI 1356823496
$17,127.93
in general payments reported to CMS, 2019-2025
24 companies · $3,958 in 2025
The $3,958 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,236 · 2022: $2,637 · 2023: $3,805 · 2024: $5,491 · 2025: $3,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $2,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,052.37 |
| Travel and Lodging | $2,202.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,844.80 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,873.00 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,762.93 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $1,354.08 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $1,052.89 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $1,045.37 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $943.42 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $927.53 | 2022-2025 | Caplyta |
| Abbvie INC. | $921.79 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $620.98 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $532.97 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $493.22 | 2022-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $342.90 | 2023-2024 | Jornay Pm |
| Corium, LLC | $334.24 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $211.35 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $203.55 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $180.47 | 2024-2025 | Cobenfy |
| Indivior INC. | $137.26 | 2023-2024 | Perseris |
| Tris Pharma INC | $93.65 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Biogen, INC. | $76.05 | 2024-2025 | Zurzuvae |
| Noven Therapeutics, LLC | $61.78 | 2024-2025 | Xelstrym, Secuado |
| Brainsway USA INC | $55.34 | 2021-2023 | |
| Owp Pharmaceuticals, INC. | $41.72 | 2023-2024 | Subvenite, Lamotrigine |
| Avion Pharmaceuticals | $16.64 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gladys Kimeli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.